ROCKVILLE, Md., July 25, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
As of September 20, 2024, GlycoMimetics Inc had a $10.6 million market capitalization, putting it in the 15th percentile of companies in the Biotechnology & Medical Research industry. GlycoMimetics ...